Dyne Therapeutics Announces Equity Investment from CureDuchenne Ventures to Support Pioneering Approach to Restoring Muscle Health in DMD

WALTHAM, Mass. –­­­ Dyne Therapeutics, a biotechnology company pioneering targeted therapies for patients with serious muscle diseases, today announced an equity investment from CureDuchenne Ventures. The funding will support Dyne’s development of precision therapeutics designed to restore muscle health in people living with Duchenne muscular dystrophy (DMD).

“Dyne’s partnership with CureDuchenne underscores our deep commitment and our sense of urgency as we work to bring life-transforming therapies to patients living with DMD and other serious muscle disorders. We appreciate the collaboration with and investment from CureDuchenne Ventures, which will help us advance our novel approach to targeting the genetic basis of DMD, with the goal of halting disease progression and restoring muscle health,” said Joshua Brumm, Dyne’s president and chief executive officer. “We look forward to continuing to collaborate with CureDuchenne and all of our partners in the Duchenne community. Together, we will improve the lives of those impacted by this devastating disease.”

Dyne’s FORCE™ platform enhances the delivery of exon skipping therapeutics to skeletal, cardiac and smooth muscle with the potential to improve efficacy and reduce dosing frequency. The company’s DMD therapeutic molecule consists of an antibody linked to an exon skipping oligonucleotide. The antibody binds to specific receptors that are highly expressed on the surface of muscle cells. Once a receptor is engaged, the antibody delivers the exon skipping oligonucleotide inside the cell, enhancing mRNA modification in the nucleus and increasing dystrophin production. This approach is designed to promote muscle health and stop the progressive loss of muscle function that characterizes DMD.

“CureDuchenne Ventures is delighted to support Dyne as part of our comprehensive approach to finding a cure for Duchenne, and we remain committed to bringing meaningful therapeutic advances to every person living with Duchenne,” said Debra Miller, founder and CEO of CureDuchenne. “We are excited about the progress of Dyne’s Duchenne program and the opportunity to rapidly advance to clinical studies. We know that progress comes from approaching research from multiple angles, and believe that Dyne’s FORCE platform holds substantial promise for advancing precision exon skipping therapies that are targeted to reach affected muscles throughout the body.”

About Dyne Therapeutics

Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit dyne-tx.com, and follow us on Twitter and LinkedIn.

About CureDuchenne

CureDuchenne is recognized as a global leader in research, patient care and innovation for improving and extending the lives of those with Duchenne muscular dystrophy. As the leading genetic killer of young boys, Duchenne affects more than 300,000 individuals living today. CureDuchenne is dedicated to finding and funding a cure for Duchenne by breaking the traditional charitable mold through an innovative venture philanthropy model that funds groundbreaking research, early diagnosis and community education. For more information on how to help raise awareness and funds needed for research, please visit www.cureduchenne.org.

For more details about CureDuchenne’s philanthropic investments, go to: https://www.cureduchenne.org/ventures/

Media Contact

Ten Bridge Communications
Stephanie Simon, (617) 581-9333
stephanie@tenbridgecommunications.com



< Back To News